Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

54.35
-0.1700-0.31%
Pre-market: 54.00-0.3500-0.64%09:24 EDT
Volume:1.05M
Turnover:56.50M
Market Cap:3.34B
PE:12.85
High:54.54
Open:54.45
Low:52.43
Close:54.52
Loading ...

Protagonist Reports Positive Top Line Results From Phase 2B Study of Icotrokinra

THOMSON REUTERS
·
10 Mar

Protagonist : Results From Phase 2B Study of Icotrokinra Showing Potential to Transform Treatment Paradigm for Patients With Ulcerative Colitis

THOMSON REUTERS
·
10 Mar

Protagonist Therapeutics : All Three Doses Met the Primary Endpoint of Clinical Response at Week 12, With a Favorable Safety Profile

THOMSON REUTERS
·
10 Mar

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire
·
10 Mar

Protagonist Therapeutics Price Target Maintained With a $54.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Mar

Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra

TIPRANKS
·
10 Mar

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)

TIPRANKS
·
10 Mar

Protagonist Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
04 Mar

Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating

TIPRANKS
·
04 Mar

Protagonist Therapeutics price target raised to $73 from $67 at BTIG

TIPRANKS
·
04 Mar

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Simply Wall St.
·
04 Mar

Protagonist Therapeutics Price Target Maintained With a $54.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

Protagonist Therapeutics’ Rusfertide: A Promising Blockbuster in the Polycythemia Vera Market with Strong Buy Rating

TIPRANKS
·
04 Mar

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga
·
04 Mar

Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $57 From $53

THOMSON REUTERS
·
04 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Melco Resorts, Chipotle, Allegro

Reuters
·
03 Mar